• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

National value-based pricing negotiation for oncology drugs - lessons from China.

作者信息

Yuan Jing, Li Minghui, Lu Z Kevin

机构信息

Department of Clinical Pharmacy & Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.

Department of Clinical Pharmacy & Translational Science, University of Tennessee Health Science Center, Memphis, TN, USA.

出版信息

Nat Rev Clin Oncol. 2023 Aug;20(8):501-502. doi: 10.1038/s41571-023-00769-8.

DOI:10.1038/s41571-023-00769-8
PMID:37173586
Abstract
摘要

相似文献

1
National value-based pricing negotiation for oncology drugs - lessons from China.肿瘤药物的国家价值定价谈判——来自中国的经验教训。
Nat Rev Clin Oncol. 2023 Aug;20(8):501-502. doi: 10.1038/s41571-023-00769-8.
2
Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.促进创新抗癌药物的可及性：中国药品价格与国家医保谈判综述。
Inquiry. 2023 Jan-Dec;60:469580231170729. doi: 10.1177/00469580231170729.
3
Progress on drug pricing negotiations in China.中国药品价格谈判进展。
Biosci Trends. 2020 Jan 20;13(6):464-468. doi: 10.5582/bst.2019.01339. Epub 2019 Dec 26.
4
Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?中国基于卫生技术评估的定价谈判：更有效的靶向抗癌药物是否意味着更高的谈判价格？
Health Res Policy Syst. 2022 Jan 3;20(1):3. doi: 10.1186/s12961-021-00810-1.
5
Consistency of new drug pricing in Korea: Bridging variations among personnel in price negotiations.韩国新药定价的一致性：弥合价格谈判人员之间的差异。
Health Policy. 2020 Sep;124(9):965-970. doi: 10.1016/j.healthpol.2020.06.003. Epub 2020 Jun 5.
6
Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions.美国医疗保险药品价格谈判：影响与未解决的问题
Value Health. 2023 Mar;26(3):394-399. doi: 10.1016/j.jval.2022.11.015. Epub 2022 Dec 9.
7
Value-based pricing: a potential solution to difficult pricing discussions and payers' negotiations.基于价值的定价：解决艰难定价讨论和与支付方谈判的潜在方案。
J Med Econ. 2024 Jan-Dec;27(1):344-347. doi: 10.1080/13696998.2024.2317119. Epub 2024 Mar 11.
8
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.中国国家医保谈判抗癌药的价格和临床获益。
Pharmacoeconomics. 2022 Jul;40(7):715-724. doi: 10.1007/s40273-022-01161-7. Epub 2022 Jun 29.
9
Pricing strategies, executive committee power and negotiation leverage in New Zealand's containment of public spending on pharmaceuticals.新西兰控制药品公共支出的定价策略、执行委员会权力和谈判筹码。
Health Econ Policy Law. 2022 Jul;17(3):348-365. doi: 10.1017/S1744133122000068. Epub 2022 Apr 6.
10
Recent Pricing Negotiations on Innovative Medicines Pilot in China: Experiences, Implications, and Suggestions.中国创新药价格谈判试点的近期情况：经验、启示与建议
Value Health Reg Issues. 2018 May;15:133-137. doi: 10.1016/j.vhri.2018.01.009. Epub 2018 May 3.

引用本文的文献

1
Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Granted Breakthrough Therapy Designation in China, 2020-2024.2020-2024 年中国突破性治疗药物认定的癌症药物的临床获益、价格和监管批准。
JAMA Netw Open. 2024 Oct 1;7(10):e2439080. doi: 10.1001/jamanetworkopen.2024.39080.
2
Impact of competition on reimbursement decisions for cancer drugs in China: an observational study.竞争对中国癌症药物报销决策的影响：一项观察性研究。
Lancet Reg Health West Pac. 2024 Jul 25;50:101157. doi: 10.1016/j.lanwpc.2024.101157. eCollection 2024 Sep.

本文引用的文献

1
Newly approved cancer drugs in China - innovation and clinical benefit.中国新获批的癌症药物——创新与临床获益。
Nat Rev Clin Oncol. 2023 Mar;20(3):135-136. doi: 10.1038/s41571-023-00728-3.
2
Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study.国家药品价格谈判政策对中国抗癌药物的利用、成本和可及性的影响：一项基于对照的中断时间序列研究。
J Glob Health. 2022 Dec 17;12:11016. doi: 10.7189/jogh.12.11016.
3
Barriers in access to oncology drugs - a global crisis.
癌症药物获取障碍——全球危机。
Nat Rev Clin Oncol. 2023 Jan;20(1):7-15. doi: 10.1038/s41571-022-00700-7. Epub 2022 Nov 15.
4
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.中国国家医保谈判抗癌药的价格和临床获益。
Pharmacoeconomics. 2022 Jul;40(7):715-724. doi: 10.1007/s40273-022-01161-7. Epub 2022 Jun 29.
5
An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed?2017-2021 年美国食品药品监督管理局批准的成人实体瘤药物评估：鹰是否已经着陆？
Nat Rev Clin Oncol. 2022 Jul;19(7):486-492. doi: 10.1038/s41571-022-00636-y. Epub 2022 Apr 28.
6
Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China.降低药价和提高药品可负担性：中国基于全国药品集中采购的效果分析。
BMJ Glob Health. 2021 Sep;6(9). doi: 10.1136/bmjgh-2021-005519.
7
Implementation of Value-based Pricing for Medicines.药品基于价值的定价实施。
Clin Ther. 2020 Jan;42(1):15-24. doi: 10.1016/j.clinthera.2019.11.006. Epub 2019 Dec 24.
8
Progress on drug pricing negotiations in China.中国药品价格谈判进展。
Biosci Trends. 2020 Jan 20;13(6):464-468. doi: 10.5582/bst.2019.01339. Epub 2019 Dec 26.
9
Recent Pricing Negotiations on Innovative Medicines Pilot in China: Experiences, Implications, and Suggestions.中国创新药价格谈判试点的近期情况：经验、启示与建议
Value Health Reg Issues. 2018 May;15:133-137. doi: 10.1016/j.vhri.2018.01.009. Epub 2018 May 3.